Norway’s Data Regulator Submits Fine on Meta Platforms to European Data Authority
(Added EU regulator’s reaction to paragraph 2) by Gwladys Fouche and Charlotte Van Campenhout OSLO/BRUSSELS, Sept 28 (Reuters) – Norway’s data regulator will submit the fine it imposed on Meta Platforms META.O to the European Data Authority (EDA), it said learned Thursday, which could make the sanction permanent and extend it to the European Union. […]
COGELEC: Results for the first half of 2023. Continuous growth in turnover: €32.6 million, +8.8%. – 09/27/2023 at 5:50 p.m.
COGELEC press release Results for the first half of 2023 Continuous growth in turnover: €32.6 million, +8.8%EBITDA up to €4.6 million, +12.0%Confirmation of growth and operational profitability prospects for the entire 2023 financial year Continued growth of activity in France and Europe The turnover for the first half of 2023 stood at €32.6 million, an […]
Ageas completes the sale of its Life insurance activities in France. – 09/25/2023 at 08:15
Ageas completes the sale of its Life insurance activities in France. Ageas today announces that all regulatory approvals relating to the sale of its French Life insurance, savings and pensions businesses to La Mutuelle Épargne Retraite Prévoyance Carac (“Carac”) have been obtained and the transaction has thus been finalized. Ageas’ Life and Pensions activities in […]
Perfect start for Rennes against Maccabi Haifa – 09/21/2023 at 9:04 p.m.
Perfect start for Rennes against Maccabi Haifa by Mattys Bernard (iDalgo) An easy victory and first place in the group. The people of Rennes had a great time at Roazhon Park. Opposed to Maccabi Haifa for this first day of the Europa League, Bruno Genesio’s players did not hold back and won 3-0. We only […]
The Importance of Energy Performance in Home Loan Approval: What Borrowers Need to Know
(Photo credits: Pixabay – annca) In addition to savings and debt ratio, banks also look at the energy performance of the property you are considering buying. When you take out a home loan, banks pay attention to your savings and your debt ratio. But not only. They also examine the distance between your future home […]
Salvatore Sirigu signs for OGC Nice – 18/09/2023 at 18:07
Salvatore Sirigu signs for OGC Nice Toto became serious again. At 36 years old and free, Salvatore Sirigu has officially joined OGC Nice. This formalization is not really a surprise, since the player had been on trial for around ten days. In the press release published on its official website, the club however did not […]
Processing of goods at the El Paso-Juarez crossing should resume in 2 or 3 days, depending on Mexico – 09/17/2023 at 6:48 p.m.
MEXICO CITY, Sept 17 (Reuters) – Cargo processing at the Bridge of the Americas on the U.S.-Mexico border between El Paso, Texas and the Mexican city of Juarez is expected to resume in two or three days, Mexico said on Sunday, after the United States announced a pause starting Monday. US Customs and Border Protection […]
Tesla jumps as analyst predicts $600 billion value boost thanks to Dojo – 09/11/2023 at 4:11 p.m.
(Updates before market opening) September 11 (Reuters) – Tesla rose 6% on Monday after Morgan Stanley said its Dojo supercomputer could enable a nearly $600 billion increase in the electric car maker’s market value by helping accelerate its foray into robotsaxis and services software. Tesla, which is already the world’s most valuable automaker, began producing […]
Intensity Therapeutics jumps to FDA ‘orphan drug’ label for cancer treatment – 09/07/2023 at 4:12 p.m.
** Intensity Therapeutics INTS.O shares rise 4.7% to 5.63 **Company says its treatment for soft tissue sarcoma (STS) has received “orphan drug” designation from the US FDA **Soft tissue sarcoma is a general term for cancers that develop in soft tissues (muscles, tendons, fat, lymphatic and blood vessels, and nerves) – NIH ** “Orphan drug” […]
Corvus Pharma makes progress with FDA approval of blood cancer drug study
** Shares of drug developer Corvus Pharmaceuticals CRVS.O rise 8% to $2.26 after the bell **The company states (link) that the US FDA has confirmed the design of a study for a late-stage trial testing its investigational drug to treat a type of blood cancer **CRVS expects to initiate registration trial of drug candidate, soquelitinib, […]